Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker PTCT
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 192 | $12.3K | 10b5-1 | Oct 9, 2026 | — | Form 144 ↗ |
| Oct 7, 2026 | Section Six Partners, L.P. Affiliate of Director | PTCT PTC Therapeutics, Inc. | 10,000 | $643.5K | 10b5-1 | Oct 7, 2026 | Form 4 ↗ 9 days later · 2,500 shares | Form 144 ↗ |
| Oct 6, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 435 | $27.9K | 10b5-1 | Oct 6, 2026 | — | Form 144 ↗ |
| Oct 5, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 1,638 | $104.9K | 10b5-1 | Oct 5, 2026 | — | Form 144 ↗ |
| Sep 30, 2026 | Steele Glenn Jr MD PHD Director | PTCT PTC Therapeutics, Inc. | 12,000 | $781.9K | 10b5-1 | Sep 30, 2026 | — | Form 144 ↗ |
| Sep 9, 2026 | Section Six Partners, L.P. Affiliate of Director | PTCT PTC Therapeutics, Inc. | 40,000 | $2.7M | 10b5-1 | Sep 9, 2026 | Form 4 ↗ 2 days later · 20,000 shares | Form 144 ↗ |
| Aug 25, 2026 amended | Section Six Partners, L.P. Affiliate of Director | PTCT PTC Therapeutics, Inc. | 50,000 | $3.6M | 10b5-1 | Aug 19, 2026 | Form 4 ↗ 3 days later · 25,000 shares | Form 144/A ↗ |
| Aug 19, 2026 | Michael Schmertzler Director | PTCT PTC Therapeutics, Inc. | 50,000 | $3.6M | 10b5-1 | Aug 19, 2026 | Form 4 ↗ 2 days later · 25,000 shares | Form 144 ↗ |
| Aug 17, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 2,813 | $201.7K | 10b5-1 | Aug 17, 2026 | Form 4 ↗ 2 days later · 2,813 shares | Form 144 ↗ |
| Aug 4, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 10,292 | $705.8K | — | Aug 4, 2026 | Form 4 ↗ 2 days later · 10,292 shares | Form 144 ↗ |
| Jul 14, 2026 | Pierre Gravier Officer | PTCT PTC Therapeutics, Inc. | 3,494 | $280.7K | — | Jul 14, 2026 | Form 4 ↗ 2 days later · 3,494 shares | Form 144 ↗ |
| Jul 9, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 2,464 | $222.4K | 10b5-1 | Jul 9, 2026 | Form 4 ↗ 4 days later · 2,464 shares | Form 144 ↗ |
| Jul 9, 2026 | Mary L. Smith Director | PTCT PTC Therapeutics, Inc. | 15,834 | $1.4M | 10b5-1 | Jul 9, 2026 | Form 4 ↗ 4 days later · 15,834 shares | Form 144 ↗ |
| Jul 7, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 24,613 | $2.2M | 10b5-1 | Jul 7, 2026 | Form 4 ↗ 1 day later · 46,774 shares | Form 144 ↗ |
| Jul 6, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 22,161 | $1.9M | 10b5-1 | Jul 6, 2026 | Form 4 ↗ 2 days later · 46,774 shares | Form 144 ↗ |
| Jul 6, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 5,079 | $427.3K | 10b5-1 | Jul 6, 2026 | Form 4 ↗ 2 days later · 5,079 shares | Form 144 ↗ |
| Jun 26, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 8,130 | $693.1K | 10b5-1 | Jun 26, 2026 | Form 4 ↗ 4 days later · 8,130 shares | Form 144 ↗ |
| Jun 25, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 20,960 | $1.8M | 10b5-1 | Jun 25, 2026 | Form 4 ↗ 1 day later · 26,283 shares | Form 144 ↗ |
| Jun 24, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 5,323 | $452.6K | 10b5-1 | Jun 24, 2026 | Form 4 ↗ 2 days later · 26,283 shares | Form 144 ↗ |
| Jun 22, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 23,749 | $1.9M | 10b5-1 | Jun 22, 2026 | Form 4 ↗ 2 days later · 23,749 shares | Form 144 ↗ |
| Jun 17, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 10,522 | $827.6K | 10b5-1 | Jun 17, 2026 | Form 4 ↗ 5 days later · 10,462 shares | Form 144 ↗ |
| Jun 17, 2026 | Christine Marie Utter Officer | PTCT PTC Therapeutics, Inc. | 19,686 | $1.5M | 10b5-1 | Jun 17, 2026 | Form 4 ↗ 5 days later · 19,686 shares | Form 144 ↗ |
| Jun 10, 2026 | Eric Pauwels Officer | PTCT PTC Therapeutics, Inc. | 21,277 | $1.6M | 10b5-1 | Jun 10, 2026 | Form 4 ↗ 2 days later · 21,277 shares | Form 144 ↗ |
| May 15, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 2,812 | $203.7K | 10b5-1 | May 15, 2026 | Form 4 ↗ 4 days later · 2,812 shares | Form 144 ↗ |
| May 14, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 2,572 | $186.4K | — | May 14, 2026 | Form 4 ↗ 1 day later · 12,572 shares | Form 144 ↗ |
| May 14, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 10,000 | $730.8K | — | May 14, 2026 | Form 4 ↗ 1 day later · 12,572 shares | Form 144 ↗ |
| May 8, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 3,540 | $279.6K | 10b5-1 | May 8, 2026 | Form 4 ↗ 4 days later · 3,540 shares | Form 144 ↗ |
| Apr 21, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 2,850 | $202.2K | — | Apr 21, 2026 | Form 4 ↗ 2 days later · 2,850 shares | Form 144 ↗ |
| Apr 6, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 2,265 | $157.3K | 10b5-1 | Apr 6, 2026 | Form 4 ↗ 2 days later · 2,265 shares | Form 144 ↗ |
| Apr 2, 2026 | Golden Lee Scott Officer | PTCT PTC Therapeutics, Inc. | 829 | $56.4K | — | Apr 2, 2026 | Form 4 ↗ 4 days later · 829 shares | Form 144 ↗ |
| Apr 1, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 52,003 | $3.6M | 10b5-1 | Apr 1, 2026 | Form 4 ↗ 2 days later · 52,003 shares | Form 144 ↗ |
| Mar 12, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 2,662 | $170.6K | — | Mar 12, 2026 | Form 4 ↗ 1 day later · 2,662 shares | Form 144 ↗ |
| Mar 10, 2026 | Stephanie Okey Director | PTCT PTC Therapeutics, Inc. | 15,167 | $1.1M | 10b5-1 | Mar 10, 2026 | Form 4 ↗ 2 days later · 15,167 shares | Form 144 ↗ |
| Mar 5, 2026 | Stephanie Okey Director | PTCT PTC Therapeutics, Inc. | 6,333 | $401.4K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 6,333 shares | Form 144 ↗ |
| Mar 5, 2026 | Almstead Zheng Yang Member of immediate family of any of th… | PTCT PTC Therapeutics, Inc. | 3,989 | $252.8K | 10b5-1 | Mar 5, 2026 | — | Form 144 ↗ |
| Mar 5, 2026 | Golden Lee Scott Officer | PTCT PTC Therapeutics, Inc. | 10,000 | $633.8K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Feb 19, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 3,019 | $207.0K | 10b5-1 | Feb 19, 2026 | Form 4 ↗ 4 days later · 3,019 shares | Form 144 ↗ |
| Feb 18, 2026 | Eric Pauwels Officer | PTCT PTC Therapeutics, Inc. | 3,019 | $209.4K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 3,019 shares | Form 144 ↗ |
| Feb 18, 2026 | Almstead Zheng Yang Member of immediate family of any of th… | PTCT PTC Therapeutics, Inc. | 65 | $4,508 | — | Feb 18, 2026 | — | Form 144 ↗ |
| Feb 18, 2026 | Neil Gregory Almstead Officer | PTCT PTC Therapeutics, Inc. | 3,056 | $212.0K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 3,121 shares | Form 144 ↗ |
| Feb 18, 2026 | Pierre Gravier Officer | PTCT PTC Therapeutics, Inc. | 2,992 | $207.5K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 2,992 shares | Form 144 ↗ |
| Feb 18, 2026 | Christine Marie Utter Officer | PTCT PTC Therapeutics, Inc. | 2,494 | $173.0K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 2,494 shares | Form 144 ↗ |
| Feb 18, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 3,081 | $213.7K | — | Feb 18, 2026 | Form 4 ↗ 1 day later · 5,894 shares | Form 144 ↗ |
| Feb 18, 2026 | Golden Lee Scott Officer | PTCT PTC Therapeutics, Inc. | 2,484 | $172.3K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 2,484 shares | Form 144 ↗ |
| Feb 18, 2026 | Matthew B. Klein Officer, Director | PTCT PTC Therapeutics, Inc. | 7,371 | $511.2K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 7,371 shares | Form 144 ↗ |
| Feb 17, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 2,813 | $194.5K | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 2 days later · 5,894 shares | Form 144 ↗ |
| Jan 9, 2026 | Mark Elliott Boulding Officer | PTCT PTC Therapeutics, Inc. | 2,314 | $180.3K | 10b5-1 | Jan 9, 2026 | Form 4 ↗ 3 days later · 6,347 shares | Form 144 ↗ |
| Jan 9, 2026 | Eric Pauwels Officer | PTCT PTC Therapeutics, Inc. | 2,746 | $213.9K | 10b5-1 | Jan 9, 2026 | Form 4 ↗ 3 days later · 7,348 shares | Form 144 ↗ |
| Jan 8, 2026 | Golden Lee Scott Officer | PTCT PTC Therapeutics, Inc. | 866 | $66.2K | — | Jan 8, 2026 | Form 4 ↗ 4 days later · 866 shares | Form 144 ↗ |
| Jan 8, 2026 | Eric Pauwels Officer | PTCT PTC Therapeutics, Inc. | 3,148 | $240.9K | 10b5-1 | Jan 8, 2026 | Form 4 ↗ 4 days later · 7,348 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances